您使用提示模式 关闭
为了方块之间的快速移动

组织机构: Daiichi Sankyo
LEI 353800XGIU2IHQGC9504

机构名称
Daiichi Sankyo Company, Limited
国家名称
日本
注册登记国
日本
行业
药品生产和生物技术
债券负债
648 百万 USD

探索最全面的数据库

80 万

债券

超过 400

定价来源

8 万

股票

9 千

ETF

以最有效的方式跟踪您的投资组合
债券筛选器
观察列表
Excel 附加组件
请求访问

最新数据在

卖价

查询已发送
无法访问
发送查询
信息提供者所提供的报价仅供参考。

简介

Daiichi Sankyo Company, Limited (第一三共株式会社 Daiichi Sankyō Kabushiki-kaisha?) is a global pharmaceutical company and the second largest pharmaceutical company in Japan. It achieved JPY 1,148.2 billion in revenue in 2013. The company owns the American biotechnology company Plexxikon, the German biotechnology company U3 Pharma and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.

奖项

新闻

2023-02-20 Moody's Investors Service affirms Daiichi Sankyo at "A2" (LT- foreign currency credit rating); outlook stable
2023-02-20 Moody's Investors Service affirms Daiichi Sankyo at "A2" (LT- local currency credit rating); outlook stable
2023-02-17 Moody's affirms Daiichi Sankyo's A2 rating; outlook stable   (Rating action commentary)
2020-08-04 Moody's Investors Service affirms Daiichi Sankyo at "A2" (LT- foreign currency credit rating); outlook stable
2020-08-04 Moody's Investors Service affirms Daiichi Sankyo at "A2" (LT- local currency credit rating); outlook stable
所有机构分析

相关文件

股票

最近一次的发行

全部显示

债券负债 (按货币)

显示所有 隐藏

代码

  • LEI
    353800XGIU2IHQGC9504
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001340156

信用和 ESG 评级

宏观经济指数

你必须 注册 才能获得访问权